Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.52)
# 761
Out of 5,030 analysts
20
Total ratings
50%
Success rate
8.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $10 → $17 | $3.70 | +359.46% | 3 | Oct 15, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $47.89 | +29.46% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.57 | +422.10% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.78 | +285.51% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.87 | +220.86% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $7.08 | +125.99% | 4 | Aug 12, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $31 → $12 | $6.25 | +92.00% | 2 | Jul 14, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.27 | +175.23% | 2 | Jun 18, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $5.87 | +394.04% | 1 | Dec 5, 2024 |
Cingulate
Oct 15, 2025
Maintains: Buy
Price Target: $10 → $17
Current: $3.70
Upside: +359.46%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $47.89
Upside: +29.46%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.57
Upside: +422.10%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.78
Upside: +285.51%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.87
Upside: +220.86%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $7.08
Upside: +125.99%
Capricor Therapeutics
Jul 14, 2025
Maintains: Buy
Price Target: $31 → $12
Current: $6.25
Upside: +92.00%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.27
Upside: +175.23%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $5.87
Upside: +394.04%